# **LABELLING**

#### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

Blister carton

### 1. Name of the medicinal product

[MA130 trade name]\* Artemether/lumefantrine 80 mg/480 mg tablets Artemether/lumefantrine

### 2. Statement of active substance

Each tablet contains 80 mg artemether and 480 mg lumefantrine.

### 3. List of excipients

See patient information leaflet for further information.

### 4. Pharmaceutical form and contents

Tablet

1 x 6 tablets

30 x 6 tablets

### 5. Method and route of administration

Oral use

Read the patient information leaflet before use.

### 6. Special warning that the medicinal product must be stored out of the reach and sight of children

Keep this medicine out of the sight and reach of children.

### 7. Other special warning(s), if necessary

## 8. Expiry date

EXP {MM/YYYY}

### 9. Special storage conditions

Do not store above 30°C. Store in the original package in order to protect the product from light.

# 10. Special precautions for disposal of unused medicinal products or waste materials derived from such medicinal products, if appropriate

# 11. Name and address of the supplier

Ajanta Pharma Ltd. Ajanta House Charkop

<sup>\*</sup> Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility. Page 2 of 4

Kandivli (West) Mumbai – 400 067 India

# 12. WHO Reference Number (Prequalification Programme)

MA130

## 13. Manufacturer's batch number

<Batch> <Lot> {number}

# 14. (Advice on) General classification for supply

Medicinal product subject to medical prescription.

## 15. Instructions on use

### MINIMUM PARTICULARS TO APPEAR ON BLISTERS

**Blisters** 

# 1. Name of the medicinal product

[MA130 trade name] † Artemether/lumefantrine 80 mg/480 mg tablets Artemether/lumefantrine

# 2. Name of the supplier

Ajanta Pharma Limited

# 3. Expiry date

EXP {MM/YYYY}

## 4. Manufacturer's batch number

<Batch> <Lot>{number}

### 5. Other

<sup>&</sup>lt;sup>†</sup> Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility. Page 4 of 4